cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
=== Colour variations === Breeders have created different colour variations, principally varying proportions of red and blue colouring. The powder blue variant is almost entirely bright blue. The reddest variety (flame red) can be confused with the red variety of honey gouramis (Trichogaster chuna). One of the most common color morphs is the turquoise / neon blue, featuring stripes of dark red and bright blue.
== External links == Molecular Weight Calculator Calculate molecular weight (molar mass) from chemical formulas Online Molar Mass Calculator with the uncertainty of M and all the calculations shown Molar Mass Calculator Online Molar Mass and Elemental Composition Calculator Stoichiometry Add-In for Microsoft Excel Archived 2011-05-11 at the Wayback Machine for calculation of molecular weights, reaction coefficients and stoichiometry. It includes both average atomic weights and isotopic weights. Molar mass: chemistry second-level course.
== Nonionic kosmotropes == Nonionic kosmotropes have no net charge but are very soluble and become very hydrated. Carbohydrates such as trehalose and glucose, as well as proline and tert-butanol, are kosmotropes.
== Louisiana Secretary of Revenue (1996–1999) == Following his first stint in state government, Kennedy returned to private law practice until 1996. That year, he was appointed secretary of the state Department of Revenue in the cabinet of Governor Mike Foster. Despite having political differences with Kennedy during his time in Roemer's administration, Foster selected Kennedy for the position and later endorsed him for the U.S. Senate. Kennedy stepped down as secretary in April 1999 and was replaced by Brett Crawford.
=== Disorders of carbohydrate transport and metabolism === 271 Disorders of carbohydrate transport and metabolism 271.0 Glycogenosis Von Gierke's disease McArdle's disease Pompe's disease 271.1 Galactosemia 271.2 Hereditary fructose intolerance 271.3 Intestinal disaccharidase deficiencies and disaccharide malabsorption Lactose intolerance Glucose intolerance 271.4 Renal glycosuria 271.8 Other specified disorders of carbohydrate transport and metabolism 271.9 Unspecified disorder of carbohydrate transport and metabolism
Sources: en.wikipedia.org
The climate of Colombia is characterized for being tropical presenting variations within six natural regions and depending on the altitude, temperature, humidity, winds and rainfall. Colombia has a diverse range of climate zones, including tropical rainforests, savannas, steppes, deserts and mountain climates. Mountain climate is one of the unique features of the Andes and other high altitude reliefs where climate is determined by elevation. Below 1,000 meters (3,281 ft) in elevation is the warm altitudinal zone, where temperatures are above 24 °C (75.2 °F). About 82.5% of the country's total area lies in the warm altitudinal zone. The temperate climate altitudinal zone located between 1,001 and 2,000 meters (3,284 and 6,562 ft) is characterized for presenting an average temperature ranging between 17 and 24 °C (62.6 and 75.2 °F). The cold climate is present between 2,001 and 3,000 meters (6,565 and 9,843 ft) and the temperatures vary between 12 and 17 °C (53.6 and 62.6 °F). Beyond lies the alpine conditions of the forested zone and then the treeless grasslands of the páramos. Above 4,000 meters (13,123 ft), where temperatures are below freezing, the climate is glacial, a zone of permanent snow and ice.
Yukimi Todo (藤堂 雪見, Tōdō Yukimi) Voiced by: Yu Miyazaki (Japanese); Aiden Call (English) Member of the Town of Winter's elite security. He's a kind and caring agent who guards Hinagiku and Sakura on Rousei and Itechou's orders. He monitored Rousei and Hinagiku's relationship during the month of the Summoning of the Four Seasons. Rintaro Shimotsuki (霜月 倫太郎, Shimotsuki Rintarō) Voiced by: Hayato Kashiwazaki (Japanese); Mauricio Ortiz-Segura (English) Member of the Town of Winter's elite security. Along with Todo, he guards the two girls on Rousei and Itechou's orders. He holds Itechou in high regard.
Axatilimab, sold under the brand name Niktimvo, is a monoclonal antibody used for the treatment of chronic graft-versus-host disease. It is a blocker of the colony stimulating factor-1 receptor. It is given by injection into a vein. The most common side effects include infections; increased blood level of liver enzymes; decreased blood level of phosphate; low red blood cell count (anemia); muscle, bone, or joint pain; increased blood level of pancreatic enzymes; low energy; increased blood level of calcium; increased blood level of a muscle enzyme; increased blood level of a bone enzyme; nausea; headache; diarrhea; cough; fever; shortness of breath; and infusion related reactions. Infusion-related reactions are common and can be serious. Axatilimab was approved for medical use in the United States in August 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Acceptance sampling uses statistical sampling to determine whether to accept or reject a production lot of material. It has been a common quality control technique used in industry. It is usually done as products leave the factory, or in some cases even within the factory. Most often a producer supplies a consumer with several items and a decision to accept or reject the items is made by determining the number of defective items in a sample from the lot. The lot is accepted if the number of defects falls below where the acceptance number or otherwise the lot is rejected. In general, acceptance sampling is employed when one or several of the following hold: testing is destructive; the cost of 100% inspection is very high; and 100% inspection takes too long. A wide variety of acceptance sampling plans is available. For example, multiple sampling plans use more than two samples to reach a conclusion. A shorter examination period and smaller sample sizes are features of this type of plan. Although the samples are taken at random, the sampling procedure is still reliable.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.